Dare Bioscience Inc (DARE)

$2.63 +0.11 (4.37%)
Market Cap 36.69M
Revenue (ttm) 1.03M
Net Income (ttm) -13.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,300.97%
Debt to Equity Ratio 0.00
Volume 625,100
Avg Vol 630,488
Day's Range N/A - N/A
Shares Out 14.56M
Stochastic %K 33%
Beta 1.09
Analysts Strong Sell
Price Target $10.25

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
HMIC
HMIC May. 12 at 11:35 PM
$DARE Just a reminder of where this can go. I sold too early it went to 9.19
0 · Reply
BiotechJedi1728
BiotechJedi1728 May. 12 at 11:22 PM
$DARE This will likely be approved and someone will swoop in. Maybe the company that bought $OGN will want another women’s health asset. https://www.linkedin.com/posts/positive-interim-phase-3-results-highlight-share-7460079253968117760-MKDN?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_campaign=share_via
0 · Reply
DanielMcharter
DanielMcharter May. 12 at 6:46 PM
$DARE Cup and handle with golden cross imminent on the daily chart.
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 5:08 PM
$DARE
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 2:53 PM
$DARE Friday?
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 2:50 PM
$DARE 📉
0 · Reply
1403tage
1403tage May. 12 at 2:48 PM
$DARE did bye 20000 shares at 2,55
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 12:48 PM
$DARE 9% become pregnant and 12% cannot continue using it because of vaginal odor. They are going to speak with the FDA since they have fewer than 250 subjects.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 11 at 7:24 PM
$DARE we need
0 · Reply
BioTerror
BioTerror May. 11 at 4:40 PM
$DARE added more 2.54
0 · Reply
Latest News on DARE
Dare Bioscience reports positive interim Phase 3 results for Ovaprene

2026-05-12T19:41:03.000Z - 19 hours ago

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

May 12, 2026, 8:00 AM EDT - 1 day ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

May 7, 2026, 8:00 AM EDT - 6 days ago

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Daré Bioscience Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 6 weeks ago

Daré Bioscience Earnings Call Transcript: Q4 2025

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 4:01 PM EDT - 6 weeks ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

On National Viagra Day, Women Finally Claim Their Turn:

Mar 23, 2026, 8:00 AM EDT - 7 weeks ago

On National Viagra Day, Women Finally Claim Their Turn:

Dare Bioscience receives NIH funding award notice for DARE-PTB1

2026-03-16T12:39:51.000Z - 2 months ago

Dare Bioscience receives NIH funding award notice for DARE-PTB1

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 16, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

2026-02-23T13:22:55.000Z - 2 months ago

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Feb 23, 2026, 8:00 AM EST - 2 months ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare announces availability of telehealth consultations for DARE to PLAY

2026-02-11T13:23:08.000Z - 3 months ago

Dare announces availability of telehealth consultations for DARE to PLAY

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

2025-12-10T13:10:49.000Z - 5 months ago

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dec 10, 2025, 8:00 AM EST - 5 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dare Bioscience announces return of rights to Oveprene

2025-12-01T13:20:39.000Z - 5 months ago

Dare Bioscience announces return of rights to Oveprene

Dare Bioscience receives $3.6M in additional grant funding

2025-11-24T13:30:31.000Z - 6 months ago

Dare Bioscience receives $3.6M in additional grant funding

Daré Bioscience Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 6 months ago

Daré Bioscience Earnings Call Transcript: Q3 2025

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 6 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dare Bioscience to host webinar on the DARE to PLAY

2025-11-11T13:10:31.000Z - 6 months ago

Dare Bioscience to host webinar on the DARE to PLAY

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Dare Bioscience to receive up to $300,000 to conduct landscape review

2025-11-03T13:20:56.000Z - 6 months ago

Dare Bioscience to receive up to $300,000 to conduct landscape review

Dare Bioscience receives $4M non-dilutive grant installment

2025-10-06T12:20:36.000Z - 7 months ago

Dare Bioscience receives $4M non-dilutive grant installment

Dare Bioscience to receive up to $499,000 to support preeclampsia research

2025-09-24T12:11:38.000Z - 8 months ago

Dare Bioscience to receive up to $499,000 to support preeclampsia research

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Dare Bioscience upgraded to Buy from Hold at Maxim

2025-09-04T11:45:08.000Z - 8 months ago

Dare Bioscience upgraded to Buy from Hold at Maxim

Daré Bioscience Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Daré Bioscience Earnings Call Transcript: Q2 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 9 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

2025-07-29T12:21:48.000Z - 10 months ago

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 10 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 10 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Dare Bioscience to host webinar on Sildenafil cream

2025-07-21T12:27:31.000Z - 10 months ago

Dare Bioscience to host webinar on Sildenafil cream

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

2025-07-15T00:37:00.000Z - 10 months ago

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene

2025-07-14T12:05:29.000Z - 10 months ago

Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene

Dare Bioscience receives $6M non-dilutive grant installment

2025-07-11T12:15:34.000Z - 10 months ago

Dare Bioscience receives $6M non-dilutive grant installment

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 10 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 11 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q1 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Apr 9, 2025, 4:00 PM EDT - 1 year ago

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Daré Bioscience Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q4 2024

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings Call Transcript: Q3 2024

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q2 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 2 years ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q1 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q4 2023

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Daré Bioscience Earnings Call Transcript: Q3 2023

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 9, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Daré Bioscience to Participate in Three November Conferences

Nov 6, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three November Conferences

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Daré Bioscience Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q2 2023

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

HMIC
HMIC May. 12 at 11:35 PM
$DARE Just a reminder of where this can go. I sold too early it went to 9.19
0 · Reply
BiotechJedi1728
BiotechJedi1728 May. 12 at 11:22 PM
$DARE This will likely be approved and someone will swoop in. Maybe the company that bought $OGN will want another women’s health asset. https://www.linkedin.com/posts/positive-interim-phase-3-results-highlight-share-7460079253968117760-MKDN?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_campaign=share_via
0 · Reply
DanielMcharter
DanielMcharter May. 12 at 6:46 PM
$DARE Cup and handle with golden cross imminent on the daily chart.
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 5:08 PM
$DARE
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 2:53 PM
$DARE Friday?
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 2:50 PM
$DARE 📉
0 · Reply
1403tage
1403tage May. 12 at 2:48 PM
$DARE did bye 20000 shares at 2,55
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 12 at 12:48 PM
$DARE 9% become pregnant and 12% cannot continue using it because of vaginal odor. They are going to speak with the FDA since they have fewer than 250 subjects.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 11 at 7:24 PM
$DARE we need
0 · Reply
BioTerror
BioTerror May. 11 at 4:40 PM
$DARE added more 2.54
0 · Reply
StackingWins999
StackingWins999 May. 8 at 12:45 PM
$DARE maybe they announce a partnership at the earnings call next week. They did that with Bayer and Ovaprene.
1 · Reply
GSP
GSP May. 7 at 9:40 PM
$NNE $DARE
0 · Reply
scottydeuce
scottydeuce May. 7 at 9:03 PM
$DARE feels like if the market was strong today this could have been at $5 - $6
2 · Reply
Green_Party
Green_Party May. 7 at 9:00 PM
$DARE Afterhours 8-k posted where DARE completed sales for about 200k investor shares (400k individual shares, almost a million dollars) in the past week. I guess as the shareprice has increased, it's seemed like a better deal. Might also ease some of the pressure of the next few months to be more intentional about their fundraising.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 7 at 7:20 PM
$DARE Next week $2? 👇
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 7 at 4:47 PM
$DARE might tell you - we have almost no working capital. Please invest in us.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 7 at 4:44 PM
$DARE 👇 can you stop it?
0 · Reply
UncleDrunk
UncleDrunk May. 7 at 3:58 PM
$DARE my wife rented a boat with her friend! Wonder where they’re going
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks May. 7 at 3:13 PM
$DARE I am here
0 · Reply
focafoca99
focafoca99 May. 7 at 12:44 PM
$DARE hosts its first-quarter 2026 results call on May 14. https://www.rapidticker.com/news/dare-daré-bioscience-to-host-first-bec09a
0 · Reply
StockSlayer18
StockSlayer18 May. 6 at 9:06 PM
$DARE pros know where to bring it .... zoom out to 5 days and you'll see where everybody is at .. above VWAP and all MA's....MACD is crossing now then up we go pass 3.50 ..... 3.40 shorts we are coming for you. dont listen to me ...im stupid.
1 · Reply
StockSlayer18
StockSlayer18 May. 6 at 9:00 PM
$DARE it's not weird.... its textbook shake and bake then accumulation ...this is a $7 ride
0 · Reply